Analysis Research

Advantest Corporation (TSE: 6857, NYSE: ATE), a global leader in test and measurement sciences, has developed two new spectroscopy systems and a new transmittance polarization analysis module for its TAS7500 product series of systems, which employ terahertz waves to perform non-destructive imaging and analysis of samples.

View more Advantest Expands Application Coverage of TAS7500 Series of Spectroscopic Imaging Systems with 2 New Systems; Transmittance Polarization Analysis Module Also Developed analysis

Sign-up for Advantest Expands Application Coverage of TAS7500 Series of Spectroscopic Imaging Systems with 2 New Systems; Transmittance Polarization Analysis Module Also Developed investment picks

2013/4/29

QIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological Data

HILDEN , Germany and REDWOOD CITY, California , April 29, 2013 /PRNewswire/ -- Ingenuity Systems is the global market leader in applications to quickly analyze and accurately interpret rapidly growing volumes of genomic data Suite of web-based applications powered by a unique expert-curated Knowledge Base eases major bottlenecks to leveraging genomic data in research and clinical diagnostics Adds leading biological interpretation resources to QIAGEN's ecosystem of sample-to-result molecular testing solutions using key technologies such as real-time PCR and next-generation sequencing (NGS) Deepens insights into disease, augmenting successful GeneGlobe content offering QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the acquisition of Ingenuity Systems, Inc., the leading provider of software solutions to efficiently and accurately analyze and interpret the

View more QIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological Data analysis

Sign-up for QIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological Data investment picks

2013/3/6

Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Genomic Research

Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing agreement today naming GenoSplice, Inc. as its preferred data analysis service provider for the new GeneChip ® Human Transcriptome Array 2.0 , the most comprehensive microarray available for alternative splicing detection.

View more Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Genomic Research analysis

Sign-up for Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Genomic Research investment picks

2013/2/14

New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI)

- Results published in Journal of the American Geriatrics Society demonstrate continuous declines in clinical cure and sustained clinical response after age 40 - JERSEY CITY, N.J. , Feb.

View more New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI) analysis

Sign-up for New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI) investment picks

2013/3/20

BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that results from a pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, indicate that the trial would not meet the pre-specified primary efficacy endpoint.

View more BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia analysis

Sign-up for BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia investment picks

2013/4/17

Concur and Oversight Systems Partnership Accelerates Advanced Travel & Expense Data Analysis

- Oversight Solution for Quickly Generating Operational Insights Now Available in Concur App Center to Concur's more than 20 million users - ATLANTA , April 17, 2013 /PRNewswire/ -- The pioneering transaction analysis software company, Oversight Systems and Concur , (Nasdaq: CNQR) , the global leader in integrated travel and expense management, today announced a partnership focused on helping customers quickly gain advanced, operational insights to uncover waste and fraud.

View more Concur and Oversight Systems Partnership Accelerates Advanced Travel & Expense Data Analysis analysis

Sign-up for Concur and Oversight Systems Partnership Accelerates Advanced Travel & Expense Data Analysis investment picks

2013/4/8

Ingenuity Systems and Affymetrix Partner to Eliminate Microarray Expression Analysis Bottleneck

REDWOOD CITY, Calif.

View more Ingenuity Systems and Affymetrix Partner to Eliminate Microarray Expression Analysis Bottleneck analysis

Sign-up for Ingenuity Systems and Affymetrix Partner to Eliminate Microarray Expression Analysis Bottleneck investment picks

2013/4/10

Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data Generated From FFPE Solid Tumor Samples for Accelerating Cancer Translational Research

Affymetrix, Inc. (NASDAQ: AFFX) and BioDiscovery announce the availability of the Nexus for OncoScan ® Software for analysis of whole genome copy number data generated from formalin-fixed, paraffin-embedded (FFPE) solid tumor samples using the OncoScan ® FFPE Express 2.0 Service .

View more Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data Generated From FFPE Solid Tumor Samples for Accelerating Cancer Translational Research analysis

Sign-up for Affymetrix and BioDiscovery Announce Software for Analysis of Whole Genome Copy Number Data Generated From FFPE Solid Tumor Samples for Accelerating Cancer Translational Research investment picks

2013/5/6

Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the results from a 12-month sub-group analysis of a National Institutes of Health (NIH), open-label, long-term research study of metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD), a rare disease estimated to affect a few thousand people around the world, often with an early age of onset.

View more Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period analysis

Sign-up for Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period investment picks

2013/2/13

Concurrent Ranked as Leader for On Demand Video Servers By Current Analysis

Concurrent (NASDAQ: CCUR) , a global leader in multiscreen video solutions and media data intelligence, today announced it has been ranked as the leader in video servers by independent research firm Current Analysis.

View more Concurrent Ranked as Leader for On Demand Video Servers By Current Analysis analysis

Sign-up for Concurrent Ranked as Leader for On Demand Video Servers By Current Analysis investment picks

2013/4/18

Construction in Florida Major-Metro Markets Increased 15.3% in Year-Over-Year Analysis, BidClerk Data Finds

For major-metro regions in Florida, including: Jacksonville, FL; Miami-Fort Lauderdale-Pompano Beach, FL; Orlando-Kissimmee-Sanford, FL; Tallahassee, FL; and Tampa-St.

View more Construction in Florida Major-Metro Markets Increased 15.3% in Year-Over-Year Analysis, BidClerk Data Finds analysis

Sign-up for Construction in Florida Major-Metro Markets Increased 15.3% in Year-Over-Year Analysis, BidClerk Data Finds investment picks

Start Premium Trial

P	F	Fund Financial Data (13,000+ funds)
P	F	Stock Financial Data (7,000+ stocks)
P	F	Stock and Fund Screeners (basic)
P	F	Investing Articles and Market Commentary
P	F	Articles Archive (>30 days)
P	F	Discuss (dozens of stock, fund, bond, and general bulletin boards)
P	F	Portfolio Manager (basic)
P	F	Morningstar Investment Classroom
P	F	Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P		Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P		Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P		Morningstar Stock and Fund Stewardship Grades
P		Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P		Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P		Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P		Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P		Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P		Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.

Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.

Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.

Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.

Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.

Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.